The German Breast Group conducts research into breast cancer, developing and implementing its own study concepts.
With the help of additional scientific research projects, we strive to gain further insights into this disease.
We are pleased to inform you that the results of the randomised phase II GeparNievo (GBG 89) study that aimed to investigate durvalumab, a PD-L1 inhibitor, in addition to an anthracycline taxane-based neoadjuvant therapy in early triple negative breast cancer (TNBC) has been published in the Annals of Oncology.
The long-term follow-up data of the phase III GeparSepto (GBG 69) study that aimed to compare weekly nab-paclitaxel with weekly sb-paclitaxel followed by epirubicin plus cyclophosphamide (EC) as neoadjuvant treatment in patients with primary breast cancer has been published in the Journal of Clinical Oncology.
Auf dem ASCO-Kongress 2019 konnten wir einige Ergebnisse und neue Studienkonzepte der GBG vorestellen.
Results of a next-generation sequencing (NGS) analysis conducted in the neoadjuvant GeparSepto study (GBG 69) have been published in the Clinical Cancer Research.
The initial results of AURORA were announced at the ESMO Breast Cancer Congress in Berlin.
Every month, we present an interesting paper.
GBG Forschungs GmbH
Martin-Behaim-Str. 12 | 63263 Neu-Isenburg | Fax +49 6102 7480-440